New mTOR inhibitor for cancer treatment


22 Mars 2016

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+


Biology / Medical



mTOR (mammalian Target Of Rapamycin) plays a central role in cancer cells. This kinase integrates signals from outside of the cell, including the quantity of available nutrient, and affects energy homeostasis by modulating signaling pathways implicated in proliferation, cell growth and survival. mTOR acts in the form of two protein complexes called mTORC1 and mTORC2. The offer proposes a new inhibitor acting via a novel mode of action on mTOR targeting the two complexes. This chemical compound is active on several cancer cell lines and not cytotoxic on fibroblasts. 

Competitive advantages:

  • Toxic effect on multiple cancer cell lines
  • Not cytotoxic on human fibroblasts
  • Novel binding site on mTOR


  • mTOR inhibition for cancer treatment

Keywords: mTOR, mTOR inhibitor, cancer, small molecule, survival pathway

Download the offer Download the offer